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Therapeutic options for patients with multiple myeloma (MM) whose disease has relapsed after a prior
autologous stem cell transplant (ASCT) include an expanding armamentarium of novel agents, often com-
bined with traditional chemotherapy, or a second ASCT, with no clear standard of care. We retrospectively
analyzed the outcomes of 75 patients who underwent salvage melphalan-based ASCT for relapsed MM at
Memorial Sloan-Kettering Cancer Center between 1995 and 2012. Conditioning was performed with
melphalan 200 mg/m2 (n ¼ 43), 180 mg/m2 (n ¼ 1), 140 mg/m2 (n ¼ 22), and 100 mg/m2 (n ¼ 9). The median
age at second ASCT was 59 years (range, 36 to 75), and 58% (n ¼ 35) were men. Of those with available data,
19% had high-risk cytogenetics (including t (4;14), p53 loss, or del 13q by karyotype) at the time of second
ASCT. Median interval between ﬁrst and salvage ASCT was 37.5 months (range, 6.9 to 111.4). Of 72 assessable
patients, 57% had chemotherapy-sensitive disease before to salvage ASCT and 43% were chemoresistant. Four
patients died within 100 days of ASCT. Response was assessed at 2 to 3 months post-ASCT, and of 71
assessable patients, 82% achieved at least a partial response, 15% had stable disease, and 3% progressed
despite salvage ASCT. After salvage ASCT, 38 patients received maintenance therapy and 14 went on to
allogeneic ASCT. The median progression-free survival (PFS) after second autograft was 10.1 months (95%
conﬁdence interval [CI], 7.6 to 13.4) and median overall survival (OS) 22.7 months (95% CI, 19.2 to 41.2).
Patients with chemosensitive relapse had a trend toward better PFS (hazard ratio [HR], .60 [95% CI, .36 to
1.02]; P ¼ .058) and signiﬁcantly longer OS (HR, .49 [95% CI, .27 to .88]; P ¼ .017) than patients with resistant
relapse. Those with high-risk cytogenetics at the time of second ASCT had higher risk of death (HR, 2.98 [95%
CI, 1.28 to 6.97]; P ¼ .012) compared with patients with standard-risk cytogenetics. Salvage ASCT is an
effective strategy for relapsed MMwith chemosensitive disease and results in comparable PFS and OS to other
salvage strategies.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
An increase in available and effective therapies for
patients with multiple myeloma (MM) has led to an
improvement in overall survival (OS) [1]. High-dose therapy
and autologous stem cell transplant (ASCT) as part of initial
therapy is complementary to novel therapies and represents
a standard for patients with MM younger than 65 years and
selected cases older than this age [2,3]. However, almost all
patients with MM will relapse after initial therapy, and most
patients with MM still die of their disease. The median timeedgments on page 472.
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ty for Blood and Marrow Transplantation.to progression after initial ASCT is 23 to 46 months and is
longer for patients who receive post-transplant maintenance
therapy [4-9]. At the time of disease recurrence, no 1 stan-
dard salvage approach is used; instead, various therapeutic
options are used, including retreatment with prior effective
therapy, use of novel or experimental agents, and, in selected
patients, allogeneic (allo-) SCT.
The ﬁrst report of the use of ASCT as salvage therapy was
published in 1995 and demonstrated a signiﬁcantly prolonged
survival compared with standard therapy [10]. Reported rates
of progression-free survival (PFS) after second salvage ASCT
have differed and have ranged from amedian of 6.8months to
4.2 years [11,12]. Here, we report the results of a retrospective
analysis of salvage ASCTconducted at our center. Our goal was
to deﬁne the outcomes of patients with access to more
modern therapy who underwent salvage ASCT and to identify
prognostic factors for prolonged PFS and OS.
Figure 1. OS for MM patients undergoing a second ASCT.
Table 1
Patient Characteristics/Clinical Factors at Second ASCT and Management
after Second ASCT
Characteristics at Second ASCT n %
Risk (27 missing)
High risk 9 19
None high risk 39 81









Neoadjuvant chemotherapy (3 N/A)
Resistant 31 43
Sensitive 41 57
Time to relapse after ﬁrst ASCT
Within 1 yr 12 16
1 yr 62 84
Median Range




Months between ﬁrst and second ASCT 37.5 6.9-111.4
Time to relapse after ﬁrst ASCT, mo 21.9 2.7-136.2
Management post salvage ASCT n %






ISS indicates International Staging System; N/A, not available; b2-micro,
Beta-2 microglobulin; LDH, lactate dehydrogenase.
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Patients
With institutional review board approval, we performed a systematic,
retrospective review of medical charts of all patients who received salvage
ASCT for MM at Memorial Sloan-Kettering Cancer Center between 1995 and
December 2012. In total, 75 patients were identiﬁed.
Deﬁnitions
A transplant was deﬁned as salvage if the patient had already received a
prior ASCT and underwent a second ASCT after evidence of disease pro-
gression, regardless of the number of lines of treatment administered after
the ﬁrst ASCT. Patients who received a planned tandem ASCT were excluded
from this study. PFS was deﬁned as the time from date of the second ASCT to
disease progression or death, whereas OS was deﬁned from the date of the
second ASCT to the date of death from any cause. Patients with high-risk
cytogenetics were deﬁned by the presence of t (4;14), del p53, and del13q
by karyotype only. Chemotherapy-sensitive disease was deﬁned by having
achieved at least a minimal response (25% reduction in serum M-protein
level or 50% reduction in urine M-protein) to salvage chemotherapy before
second ASCT.
Response
Response and progression were deﬁned according to the International
Myeloma Working Group criteria [13,14]. A complete response was deﬁned
as negative immunoﬁxation of serum and urine, disappearance of soft tissue
plasmacytoma, and <5% plasma cells in the bone marrow. Very good partial
response was deﬁned as serum and urine M-protein detectable only by
immunoﬁxation or as a 90% or greater reduction in serum M-protein plus a
urineM-protein level<100mg per 24 hours. Partial responsewas deﬁned as
a reduction in serum M-protein of at least 50% and by a reduction of at least
90% or an absolute value<200mg per 24 hours in urine M-protein. Minimal
response was deﬁned by reduction in the serum M-protein by at least 25%
but less than 50% and reduction in the urine M-protein by 50% to 89%. Stable
disease was deﬁned as not meeting any response criteria, and progressive
disease was deﬁned as a conﬁrmed increase >25% of M-protein from
baseline. Relapse was deﬁned as the reappearance of serum or urineM-protein or the development of new bone lesions, plasmacytoma, or hy-
percalcemia. Response post-ASCT was assessed at a maximum of 80 to
100 days post-transplantation, and patients were followed approximately
every 3 months thereafter.Statistical Analysis
Cox proportional hazard model was used to assess the associations
between the following variables collected before second ASCT with OS and
PFS: time to relapse after ﬁrst ASCT, time between ﬁrst and second ASCT
(18 months versus <18 months), the presence of high-risk cytogenetics,
and chemosensitive disease. Time-dependent Cox regression was used to
evaluate the post-second ASCT factors of maintenance therapy and allo-
ASCT after second ASCT. Univariate factors signiﬁcant at the .05 level were
included in multivariate models for OS and PFS. Survival curves of patients
were prepared using the Kaplan-Meier method.RESULTS
Patient Characteristics
Patient characteristics at time of second transplants are
shown in Table 1. In total, 75 patients (45 men and 30
women) received second ASCT for relapsedMM at our center
from January 1998 to December 2012. Median age at second
transplant was 59 years (range, 36 to 75). Themedian time to
relapse after ﬁrst ASCTwas 21.9months. Themedian number
of months between ﬁrst and second transplant was 37.7
(range, 6.9 to 111.4). Median number of chemotherapies
before second transplant was 1 (range, 1 to 4). Sixteen pa-
tients had 2 lines of therapies before transplant, 12 patients
had 3 lines, and 5 patients had 4 lines of therapies before
transplant. The most likely explanation for this could be
physician’s discretion to take the patient to transplant even if
they were not responding to salvage therapy.
In total, 31 patients had resistant/refractory disease going
into the transplant. Of these 31,12 patients were treated with
a single line of therapy before transplant consisting of agents
either alone or in combination (eg, thalidomide, Decadron,
velcade, Cytoxan, cisplatin, etoposide, and revlimid). Eight
patients had 2 lines of treatment, 7 patients had 3 lines of
treatment, and 4 patients had 4 lines of treatment. Of pa-
tients with available data, 19% had high-risk disease at time
of second transplant. Thirty-eight patients (51%) received
thalidomide, lenalidomide, or bortezomib maintenance
therapy after the second transplant. Fourteen patients (19%)
received allo-ASCT after their second autologous transplant.
Figure 2. PFS for MM patients undergoing a second ASCT.
Table 3
Multivariate Analysis of OS and PFS (n ¼ 47)
HR (95% CI) P
OS
High risk vs. standard risk (ref)
at second ASCT
2.85 (1.15, 7.11) .024
Chemosensitive vs. resistance (ref) .48 (.21, 1.09) .081
Time to relapse after ﬁrst ASCT
(unit increment ¼ 1 month)
.99 (.97, 1.02) .583
PFS
High risk vs. not high risk (ref)
at second ASCT
2.69 (1.09, 6.64) .031
Time to relapse after ﬁrst ASCT
(unit increment ¼ 1 month)
.98 (.96, 1.00) .024
Univariate variables signiﬁcant at the level of .05, and patients with infor-
mation available for these variables were included in the multivariate
analysis.
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Response was assessed between 2 and 3 months post-
transplant. Four patients died within 100 days of ASCT,
accounting for 5% transplant-related mortality. Of 71
assessable patients, 17% (n ¼ 12) achieved complete
response, 34% (n ¼ 24) achieved partial response, 31%
(n ¼ 22) achieved very good partial response, 15% (n ¼ 11)
had stable disease, and 3% (n¼ 2) had progression of disease.
The overall response to second ASCT was 77% (at least partial
response). With a median follow-up of 33.3 months (range,
3.2 to 92.9) for survivors, the median OS was 22.7 months
(95% conﬁdence interval [CI], 19.2 to 41.2) and the median
PFS was 10.1 months (95% CI, 7.6 to 13.4) (Figures 1 and 2). At
the time of last follow up, 53 patients had progressed, 48
died, and 12 remained event-free.Prognostic Factors
Conventional karyotype analysis was available in 43 pa-
tients and ﬂuorescent in situ hybridization in 38. Of thoseTable 2
Univariate Analysis of OS and PFS
HR (95% CI) P
OS
High risk vs. not high risk (ref) 2.98 (1.28, 6.97) .012
Interval between ﬁrst ASCT and second
ASCT  18 months vs. <18 months (ref)
.66 (.30, 1.49) .318
Chemosensitive vs. resistance (ref) .49 (.27, .88) .017
Melphalan 200 vs. <200 (ref) 1.04 (.59, 1.85) .888
After ﬁrst ASCT relapse  1
year vs. <1 year (ref)
.67 (.33, 1.35) .261
Maintenance yes vs. no (ref)* 1.00 (.55, 1.83) .996
Allo-SCTyes vs. no (ref)* .98 (.45, 2.12) .978
PFS
High risk vs. not high risk (ref) 3.59 (1.48, 8.73) .005
Interval between ﬁrst ASCT and second
ASCT  18 months vs. <18 months (ref)
.74 (.36, 1.51) .407
Chemosensitive vs. resistance (ref) .60 (.36, 1.02) .058
Melphalan 200 vs. <200 (ref) .95 (.57, 1.57) .831
After ﬁrst ASCT relapse  1
year vs. <1 year (ref)
.61 (.32, 1.14) .120
Maintenance yes vs. no (ref)* 1.06 (.63, 1.78) .831
Allo-SCT yes vs. no (ref)* .81 (.38, 1.72) .577
ref indicates reference group.
* Time-dependent variable Cox model analysis.with available data, 19% had high-risk cytogenetics at the
time of second ASCT. Compared with patients who had
standard-risk cytogenetics at the time of second ASCT, pa-
tients with high-risk abnormalities had signiﬁcantly worse
PFS (P ¼ .005) and OS (P ¼ .012) (Table 2).
It has been shown in previous studies that the duration of
response to initial therapy may predict response to subse-
quent therapy [15,16]. Indeed, when time to relapse after
initial ASCT was evaluated as a continuous variable, it was
signiﬁcantly associated with both PFS (P ¼ .002) and OS
(P¼ .013). However, therewas no signiﬁcant difference in PFS
and OS when comparing patients who received a second
ASCTwithin 18months of the ﬁrst transplant with thosewho
had a longer interval between transplants.
Response to therapy before second ASCT was determined.
Chemosensitivity (deﬁned as at least minimal response) at
time of second transplant was associated with better OS
(P ¼ .017) and a trend toward better PFS (P ¼ .058). Other
factors evaluated for impact on outcomes are shown in
Table 2. In multivariate analysis, high-risk cytogenetic at the
time of second ASCT remained signiﬁcant for both PFS and
OS. Chemosensitivity and time from ﬁrst transplant to
relapse were no longer statistically signiﬁcant in the PFS
model (Table 3). Univariate and multivariate analysis wereTable 4
Univariate Analysis of OS and PFS in Patients Who Received a Second ASCT
Between 2007 and 2012 (n ¼ 40)
HR (95% CI) P
OS
High risk vs. not high risk (ref) 3.18 (1.06, 9.58) .039
Interval between ﬁrst ASCT and second
ASCT  18 months vs. <18 months (ref)
.04 (0, .64) .023
Chemosensitive vs. resistance (ref) .26 (.10, .71) .009
Melphalan 200 vs. <200 (ref) 1.09 (.41, 2.92) .860
After ﬁrst ASCT relapse  1
year vs. <1 year (ref)
.30 (.10, .91) .034
Maintenance yes vs. no (ref)* .98 (.38, 2.57) .973
Allo-SCT yes vs. no (ref)* 2.52 (.92, 6.95) .073
PFS
High risk vs. not high risk (ref) 3.95 (1.3, 12.04) .016
Interval between ﬁrst ASCT and second
ASCT  18 months vs. <18 months (ref)
.05 (0, .85) .038
Chemosensitive vs. resistance (ref) .34 (.14, .82) .017
Melphalan 200 vs. <200 (ref) 1.14 (.48, 2.68) .766
After ﬁrst ASCT relapse  1
year vs. <1 year (ref)
.23 (.07, .72) .012
Maintenance yes vs. no (ref)* 1.44 (.64, 3.26) .381
Allo-SCT yes vs. no (ref)* 2.10 (.83, 5.33) .119
* Time-dependent variable Cox model analysis.
Table 5
Multivariate Analysis of OS and PFS in Patients Who Received Second ASCT
Between 2007 and 2012 (n ¼ 34)
HR (95% CI) P
OS
High risk vs. not high risk (ref) 3.65 (1.18, 11.24) .024
Interval between ﬁrst ASCT and second
ASCT  18 months vs. <18 months (ref)
.03 (0, .53) .016
PFS
High risk vs. not high risk (ref) 4.6 (1.47, 14.40) .009
Interval between ﬁrst ASCT and second
ASCT  18 months vs. <18 months (ref)
.04 (0, .64) .023
Univariate variables signiﬁcant at the level of .05, and patients with infor-
mation available for these variables were initially included in the multi-
variate analysis. Backward selection method was used and only signiﬁcant
variables were kept in the model.
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between 2007e2012 as shown in Tables 4 and 5.DISCUSSION
Despite many advances in the treatment of MM, a cure
has been elusive, and patients typically require sequential
regimens to control the disease for as long as possible. High-
dose melphalan supported by ASCT in ﬁrst remission is
currently accepted as gold standard consolidation for pa-
tients with MM deemed ﬁt. However, prolonged PFS post-
ASCT is uncommon, and selection of optimal treatment for
disease relapse is the major decision for patients and treating
clinicians [6,15].
This retrospective analysis indicates that patients with
relapsed MM can beneﬁt from a second ASCT with median
PFS of 10.3 months and OS of almost 2 years, which is
comparable with salvage therapy with currently available
novel agents [17-21]. Five percent of patients died from
transplant-related complications. Most of our patients (90%)
had received either proteasome inhibitors or immune-
modulating (IMID) therapies as part of initial induction or
as salvage before second ASCT. Similar to others, we found
that a longer disease remission after initial ASCT and an
inherent response of the disease to salvage therapy were
signiﬁcantly associated with better outcomes. In our study,
patients who were cytogenetically deﬁned as “standard risk”
rather than those with high-risk abnormalities derived the
most beneﬁt from this approach. On the other hand, the dose
of melphalan and receiving post-ASCT maintenance or allo-
ASCT as consolidation after salvage autologous transplant
did not impact outcomes.
It is important to recognize the limitations of this retro-
spective study. First, the sample size was small and distrib-
uted over more than 10 years. Yet, most patients received
proteasome inhibitors and IMIDs as part of their reinduction
regimen, but these were most often ﬁrst- or second-
generation agents. Second, the induction regimens were
heterogeneous, as were the number of prior lines of therapy.
Therefore, these data do not guide decision making as to
when to perform a second ASCT. Finally, the denominator of
how many patients could have been eligible for salvage
transplant is unknown because of the retrospective nature of
the data. Although patients who die of relapsing disease
quickly were not eligible for salvage transplant, which selects
for more favorable patients, this study was performed when
we and other centers were participating in early phase trials
studying second- and third-generation IMIDs and protea-
some inhibitors. Perhaps only patients presumed to be athigh risk of disease progression were offered second
transplants.
In all reports, chemosensitivity and remission after ﬁrst
autograft emerge as the most important prognostic factors
for subsequent long-term disease control [10,16,22,23].
However, whether patients with remissions beyond
12 months [24], 18 months [22], 24 months [25], or
36 months [26] should be offered this therapy remains un-
clear. Other reports identiﬁed the number of lines of prior
therapy had a signiﬁcant impact on outcomes and suggested
that salvage ASCT should not be relegated to a “last-ditch
effort” in patients who have failed all prior therapies but
should be considered an integral component of initial salvage
strategies [27].
The ﬁrst prospective randomized trial studying ASCT
versus less intensive alkylating agent consolidation (weekly
cyclophosphamide) after ﬁrst relapse and reinduction with
a bortezomib-containing regimen has been published [28].
This trial showed a clear advantage in terms of time to
progression, 19 versus 11 months (P < .0001), for the
transplant arm compared with the chemotherapy arm; in
fact, the trial was stopped early because it met its pre-
deﬁned endpoint. However, with limited follow-up, an OS
difference was not shown. One could argue, however, that
cyclophosphamide alone is not an effective agent and
continuing combination treatment may have comparable
outcomes. A PFS of 17.9 months was demonstrated in a
study where a combination of bortezomib, thalidomide, and
dexamethasone was used for 1 year in patients with
relapsed/progressing disease post-transplant [29]. Taken
together, a prospective, randomized, controlled trial
comparing second ASCT versus continuing new treatment
regimens is now warranted.
The role of second salvage ASCT in the context of the
current treatment landscape that often includes mainte-
nance after initial ASCT remains unknown. One can speculate
that the longer duration of remission after initial transplant
when maintenance is used may translate into improved
outcomes after a second transplant. Alternately, mainte-
nance therapy may select for more resistant clones and lead
to shorter remission duration after a second transplant.
Interestingly, 1 group reported longer time to progression
after the second rather than the ﬁrst ASCT, suggesting the
persistence of more sensitive subclones in the absence of
maintenance [23]. The availability of second- and even third-
generation proteasome inhibitors and IMIDs may also limit
the applicability of our data. Importantly, prospective studies
that include pomalidomide and/or carﬁlzomib-based rein-
duction and randomization to transplant or no transplant are
ongoing or planned and are critical. Within this context, it
will be essential to collect symptom burden and other quality
of life data to have a broader understanding of the results of
these studies. However, it is reassuring that to date most
groups found the frequency and intensity of toxicities after
the ﬁrst and second transplantation to be similar [30].
Identiﬁcation of biological parameters that can predict
response to a given treatment, including high-dose
melphalan, would be help with selection of the most
appropriate salvage therapy for individual patients. In our
study, patients with high-risk cytogenetics were less likely to
beneﬁt from a second salvage ASCT; however, this is in
contrast to others who reported that adverse cytogenetics
had no signiﬁcant impact on outcomes after salvage ASCT
[24]. This will best be assessed in the context of the afore-
mentioned prospective, randomized clinical trials.
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therapies for the treatment of MM, patients eventually die
from their disease. With a limited armamentarium of effec-
tive treatment options, a second ASCTat the time of relapse is
an option that has been associated with reasonable response
rates and PFS. Patients with refractory disease and limited
remissions after initial transplant to date have had limited
beneﬁt with this approach andmay be reasonable candidates
for experimental therapies and/or allo-ASCT. However, next-
generation reinduction and the routine use of post-
transplant/consolidation maintenance may considerably
change the outcomes with this approach.ACKNOWLEDGMENTS
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